CL2019001511A1 - Derivado de benzimidazol sustituido como modulador de la actividad del factor de necrosis tumoral. - Google Patents
Derivado de benzimidazol sustituido como modulador de la actividad del factor de necrosis tumoral.Info
- Publication number
- CL2019001511A1 CL2019001511A1 CL2019001511A CL2019001511A CL2019001511A1 CL 2019001511 A1 CL2019001511 A1 CL 2019001511A1 CL 2019001511 A CL2019001511 A CL 2019001511A CL 2019001511 A CL2019001511 A CL 2019001511A CL 2019001511 A1 CL2019001511 A1 CL 2019001511A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- modulator
- necrosis factor
- tumor necrosis
- factor activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
2-(5-{1-[2-(DIFLUOROMETOXI)-6-FLUOROBENCIL]-2-METIL-1HBENCIMIDAZOL-6-IL}PIRIMIDIN-2-IL)PROPAN-2-OL, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, QUE SON POTENTES MODULADORES DE LA ACTIVIDAD DEL TNFΑ HUMANO, SON POR LO TANTO BENEFICIOSOS EN EL TRATAMIENTO Y/O PREVENCIÓN DE DIVERSAS DOLENCIAS HUMANAS, INCLUYENDO TRASTORNOS AUTOINMUNES E INFLAMATORIOS; TRASTORNOS NEUROLÓGICOS Y NEURODEGENERATIVOS; DOLOR Y TRASTORNOS NOCICEPTIVOS; TRASTORNOS CARDIOVASCULARES; TRASTORNOS METABÓLICOS; TRASTORNOS OCULARES; Y TRASTORNOS ONCOLÓGICOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1620948.8A GB201620948D0 (en) | 2016-12-09 | 2016-12-09 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001511A1 true CL2019001511A1 (es) | 2019-09-06 |
Family
ID=58222106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001511A CL2019001511A1 (es) | 2016-12-09 | 2019-06-04 | Derivado de benzimidazol sustituido como modulador de la actividad del factor de necrosis tumoral. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10669263B2 (es) |
| EP (1) | EP3551624B1 (es) |
| JP (1) | JP6983238B2 (es) |
| KR (1) | KR20190091328A (es) |
| CN (1) | CN110023300B (es) |
| AU (1) | AU2017371443B2 (es) |
| BR (1) | BR112019008766A2 (es) |
| CA (1) | CA3041081A1 (es) |
| CL (1) | CL2019001511A1 (es) |
| CO (1) | CO2019007115A2 (es) |
| CY (1) | CY1124158T1 (es) |
| DK (1) | DK3551624T3 (es) |
| EA (1) | EA037199B1 (es) |
| ES (1) | ES2853981T3 (es) |
| GB (1) | GB201620948D0 (es) |
| HR (1) | HRP20210405T1 (es) |
| HU (1) | HUE054184T2 (es) |
| IL (1) | IL266874B (es) |
| LT (1) | LT3551624T (es) |
| MX (1) | MX2019006033A (es) |
| PL (1) | PL3551624T3 (es) |
| PT (1) | PT3551624T (es) |
| RU (1) | RU2019120527A (es) |
| SG (1) | SG11201903655VA (es) |
| SI (1) | SI3551624T1 (es) |
| WO (1) | WO2018104534A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1262180A4 (en) * | 2000-02-18 | 2005-06-01 | Takeda Pharmaceutical | TNF-ALPHA HEMMER |
| US8163777B2 (en) * | 2006-03-23 | 2012-04-24 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| CN104428293B (zh) * | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
| HUE056133T2 (hu) | 2014-10-03 | 2022-01-28 | UCB Biopharma SRL | Fuzionált pentaciklusos imidazol-származékok |
-
2016
- 2016-12-09 GB GBGB1620948.8A patent/GB201620948D0/en not_active Ceased
-
2017
- 2017-12-08 BR BR112019008766A patent/BR112019008766A2/pt not_active IP Right Cessation
- 2017-12-08 MX MX2019006033A patent/MX2019006033A/es unknown
- 2017-12-08 ES ES17811318T patent/ES2853981T3/es active Active
- 2017-12-08 PT PT178113189T patent/PT3551624T/pt unknown
- 2017-12-08 SG SG11201903655VA patent/SG11201903655VA/en unknown
- 2017-12-08 CA CA3041081A patent/CA3041081A1/en not_active Abandoned
- 2017-12-08 LT LTEP17811318.9T patent/LT3551624T/lt unknown
- 2017-12-08 RU RU2019120527A patent/RU2019120527A/ru not_active Application Discontinuation
- 2017-12-08 US US16/349,734 patent/US10669263B2/en active Active
- 2017-12-08 WO PCT/EP2017/082092 patent/WO2018104534A1/en unknown
- 2017-12-08 JP JP2019529481A patent/JP6983238B2/ja active Active
- 2017-12-08 EP EP17811318.9A patent/EP3551624B1/en active Active
- 2017-12-08 DK DK17811318.9T patent/DK3551624T3/da active
- 2017-12-08 HU HUE17811318A patent/HUE054184T2/hu unknown
- 2017-12-08 AU AU2017371443A patent/AU2017371443B2/en not_active Ceased
- 2017-12-08 KR KR1020197019326A patent/KR20190091328A/ko not_active Application Discontinuation
- 2017-12-08 PL PL17811318T patent/PL3551624T3/pl unknown
- 2017-12-08 CN CN201780073716.6A patent/CN110023300B/zh not_active Expired - Fee Related
- 2017-12-08 EA EA201991294A patent/EA037199B1/ru unknown
- 2017-12-08 SI SI201730672T patent/SI3551624T1/sl unknown
-
2019
- 2019-05-26 IL IL266874A patent/IL266874B/en unknown
- 2019-06-04 CL CL2019001511A patent/CL2019001511A1/es unknown
- 2019-07-02 CO CONC2019/0007115A patent/CO2019007115A2/es unknown
-
2021
- 2021-03-10 HR HRP20210405TT patent/HRP20210405T1/hr unknown
- 2021-03-22 CY CY20211100245T patent/CY1124158T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201620948D0 (en) | 2017-01-25 |
| CY1124158T1 (el) | 2022-05-27 |
| EP3551624A1 (en) | 2019-10-16 |
| CA3041081A1 (en) | 2018-06-14 |
| JP2020502081A (ja) | 2020-01-23 |
| RU2019120527A3 (es) | 2021-01-13 |
| EA201991294A1 (ru) | 2019-12-30 |
| IL266874A (en) | 2019-07-31 |
| US10669263B2 (en) | 2020-06-02 |
| RU2019120527A (ru) | 2021-01-13 |
| BR112019008766A2 (pt) | 2019-07-16 |
| EP3551624B1 (en) | 2021-01-20 |
| SI3551624T1 (sl) | 2021-04-30 |
| KR20190091328A (ko) | 2019-08-05 |
| CN110023300A (zh) | 2019-07-16 |
| LT3551624T (lt) | 2021-04-26 |
| MX2019006033A (es) | 2019-08-12 |
| PT3551624T (pt) | 2021-02-01 |
| AU2017371443A1 (en) | 2019-05-23 |
| CO2019007115A2 (es) | 2019-07-10 |
| IL266874B (en) | 2022-03-01 |
| DK3551624T3 (da) | 2021-03-22 |
| HUE054184T2 (hu) | 2021-08-30 |
| AU2017371443B2 (en) | 2021-07-22 |
| HRP20210405T1 (hr) | 2021-04-16 |
| PL3551624T3 (pl) | 2021-07-05 |
| SG11201903655VA (en) | 2019-05-30 |
| US20190284170A1 (en) | 2019-09-19 |
| WO2018104534A1 (en) | 2018-06-14 |
| JP6983238B2 (ja) | 2021-12-17 |
| ES2853981T3 (es) | 2021-09-20 |
| EA037199B1 (ru) | 2021-02-18 |
| CN110023300B (zh) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001188A1 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos. | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| CL2017001117A1 (es) | Métodos para tratar enfermedades oculares. | |
| EA201401350A1 (ru) | Бензимидазолы, модулирующие tnf-альфа | |
| CR20160583A (es) | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea como inhibidor de trka cinasa | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| CR20170167A (es) | Derivados de imidazol pentacíclicos fusionados | |
| UY36021A (es) | Proteìnas fc multimèricas | |
| PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
| UY35738A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
| PE20181165A1 (es) | Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue | |
| CR20160480A (es) | Terapia genetica para la retinitis pigmentaria | |
| PE20191407A1 (es) | Uso de gaboxadol en el tratamiento de tinnitus | |
| CL2016002497A1 (es) | “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct | |
| TN2019000033A1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| EA201792686A1 (ru) | Производные индазола в качестве модуляторов активности tnf | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX2018006226A (es) | Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo. | |
| WO2018187698A3 (en) | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists | |
| MX2018005035A (es) | Formulaciones de liberacion sostenida de anestesicos locales. | |
| CO2019012856A2 (es) | Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf | |
| EA201892144A1 (ru) | Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf | |
| BR112018069941A2 (pt) | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf | |
| CL2019001511A1 (es) | Derivado de benzimidazol sustituido como modulador de la actividad del factor de necrosis tumoral. | |
| CL2017001390A1 (es) | Camkk1 como un nuevo regenerativo terapéutico |